References
- S. Ahmad and N. Dixit, Silymarin: a review of pharmacological aspects and bioavailability enhancement approach, Ind. J. Pharm. 39 (2007) 172-179; DOI: 10.4103/0253-7613.36534.
- S. Abrol, T. Aman and K. O. Parkash, Comparative study of different silymarin formulations: formulation, characterization and in vitro/in vivo evaluation, Curr. Drug Deliv. 2 (2005) 45-51; DOI: 1567-2018/05 $50.00+.00.
- P. D. Nakhat, R. A. Naidu, I. B. Babla, S. Khan and P. G. Yeole, Design and evaluation of silymarin-HP-β-CD solid dispersion tablets, J. Pharm. Sci. 69 (2007) 287-289; DOI: 10.4103/0250-474X.33160.
- J. H. Hu and F. Q. Li, Improvement of the dissolution rate of silymarin by means of solid dispersions, Chem. Pharm. Bull. 52 (2004) 972-973; DOI: 10.1248/cpb.52.972.
- S. W. Jong, T. S. Kim, J. H. Park, and S. C. Chi, Formulation and biopharmaceutical evaluation of silymarin using SMEDDS, Arch. Pharm. Res. 30 (2007) 82-89; DOI: 10.1007/BF02977782.
- W. Wachter and H. Zeskae, Flavanolignan Preparation and their Use for Preparation of Pharmaceuticals, U.S. Pat. 5,906,991, 25 May 1999.
- D. Voinovich, B. Perrisuiti and L. Maggaroto, Solid state mechanochemical simultaneous activation of the constituents of the Silybum marianum phytochemical complex with crosslinked polymers, J. Pharm. Sci. 3 (2008) 1-14; DOI: 10.1002/jps.21417.
- J. B. Dressman and L. Christian, Improving drug solubility for oral delivery using solid dispersions, Eur. J. Pharm. BioPharm. 50 (2000) 47-60; DOI: 10.1016/S0939-6411(00)00076-X.
- Y. Rane, R. Mashru, M. Sankalia and J. Sankalia, Effect of hydrophilic swellable polymers on dissolution enhancement of carbamazepine solid dispersions studied using response surface methodology, AAPS Pharm. Sci. Tech. 8 (2007) Article 27; DOI: 10.1208/pt0802027.
- A. Avani and M. Renuka, Formulation development of taste-masked rapidly dissolving films of cetirizine hydrochloride, Pharm. Tech. 33 (2009) 48-56.
- S. J. Hwang, D. H. Won, M. S. Kim, S. Lee and J. S. Park, Improved physicochemical characteristics of felodipine solid dispersion particles by supercritical anti-solvent precipitation process, Int. J. Pharm. 301 (2005) 199-208; DOI: 10.1016/j.ijpharm.2005.05.017.
- United States Pharmacopoeia 24/National Formulary 19, USP Convention, Rockville 2000, p. 2235.
- P. Costa and L. J. Manuel Sousa, Modelling and comparison of dissolution profiles, Eur. J. Pharm. Sci. 13 (2001) 123-133; DOI: 10.1016/S0928-0987(01)00095-1.
- J. W. Moore and H. H. Flanner, Mathematical comparison of dissolution profiles, Pharm. Tech. 20 (1996) 64-74.
- R. P. Patel and M. M. Patel, Solid-state characterization and dissolution properties of lovastatin hydroxypropyl-beta-cyclodextrin inclusion complex, Pharm. Tech. 2 (2007) 72-81.
- S. Baboota, M. Dhalival and K. Kohli, Physicochemical characterization, in vitro dissolution behaviour, and pharmacodynamic studies of rofecoxib-cyclodextrin inclusion compounds: preparation and properties of rofecoxib hydroxypropyl β-cyclodextrin inclusion complex: a technical note, AAPS Pharm. Sci. Tech. 6 (2005) 83-90; DOI: 10.1208/pt060114.
- M. A. Khan and A. A. Karnachi, Box-Behnken design for the optimization of formulation variables of indomethacin co-precipitates with polymer mixtures, Int. J. Pharm. 131 (1996) 9-17; DOI: 10.1016/0378-5173(95)04216-4.
- S. Torrado, P. D. Torre and S. Torrado, Preparation, dissolution and characterization of pranziquantel solid dispersions, Chem. Pharm. Bull. 47 (1999) 1629-1633; DOI: 99A1042280.
- S. R. Vikram, M. R. Shelake, S. S. Shetty, A. B. Chavan-Patil, Y. V. Pore and S. G. Late, Enhanced solubility and dissolution rate of lamotrigine by inclusion complexation and solid dispersion technique, J. Pharm. Pharm. Sci. 60 (2008) 1121-1129; DOI: 10.1211/jpp.60.9.0002.
- K. Okimoto, M. Miyake, R. Ibuki, M. Yasumura, N. Ohnishi and T. Nakai, Dissolution mechanism and rate of solid dispersion particles of nilvadipine with hydroxypropylmethylcellulose, Int. J. Pharm. 159 (1997) 85-93; DOI: 10.1016/S0378-5173(97)00274-3.
- M. S. Nagarsenker and M. S. Joshi, Celecoxib cyclodextrin systems: characterization and evaluation of in vitro and in vivo advantage, Drug Dev. Ind. Pharm. 31 (2005) 169-178; DOI: 10.1081/DDC-200047795.